openPR Logo
Press release

Oncology Drugs Market Estimated to Record Highest CAGR by 2026 With Top Companies Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer

07-12-2019 12:30 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Oncology Drugs

Oncology Drugs

Group of cells that lose contact inhibition growth mechanism leads to development of tumor, which is potent to grow infinitely at its origin or can invade into blood stream and lead to tumor at different sites. Based on the location ability of tumor cancer, it is classified as benign tumor or malignant tumor, respectively. The global oncology drugs market is segmented by drug type, by cancer type, and by distribution channel. Based on the drug type, the market is segmented into cytotoxic drugs, targeted drugs, and hormonal drug. Targeted drugs specifically target cancerous cells, which helps in reducing the side effects of the drugs. This in turn propels growth of targeted drugs segment.

Get The PDF Brochure of This Business Report : www.coherentmarketinsights.com/insight/request-pdf/2332

Market Dynamics

Increasing drug approvals and robust pipeline for novel therapeutic agents are some of the key factors driving the oncology drugs market growth. For instance, in August 2017, Tisagenlecleucel (Kymriah), a drug developed by Novartis was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric and young adults with refractory or relapsed Acute Lymphoblastic Leukemia (ALL). Moreover, increasing prevalence of various types of cancer is also fueling the oncology drugs market growth. The global oncology drugs market size is estimated to be valued at US$ 77.3 billion in 2018 and is expected to witness a CAGR of 12.3% over the forecast period (2018 – 2026).

Increasing preference of immunotherapy for the treatment of cancer is driving the oncology drugs market growth

Key companies in the oncology drugs market are focused on targeting cancer treatment based on personalized medicines. According to Tufts Center for the Study of Drug Development (CSDD), 2015 report, 73% of the cancer medicines in the development have potential to be personalized medicine. Several researches are focused on targeting cancer at molecular level to offer new cancer treatments. According to an article published in The Biopharmaceutical Pipeline, 2013, new molecular entity for cancer treatment holds 80% share in the total pipeline products for cancer treatment. According to same source, the total number of potential first-in-class projects for cancer are 4,358 out of total 5,473 cancer projects.

Market players are focused on mergers with research institutes and acquisition of small market players

Key players in the oncology drugs market are focused on strategies such as mergers with research institutes and acquisition of small market players in order to enhance their market share. This in turn is expected to boost the market growth over the forecast period. Major players operating in the global oncology drugs market include, Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer AG, and Amgen Inc.

Request Customization : www.coherentmarketinsights.com/insight/request-customizat...

Presence of key market players and increasing drug approvals are attributing to the highest share of North America market in the global oncology drugs market

Regional oncology drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America oncology drugs market holds dominant position in the global oncology drugs market. Advanced medical treatment options available for cancer in economies such as the U.S. and increasing survival rate are key factors driving the market growth. For instance, according to the American Association for Cancer Research’s 2015 report, the number of survivors suffering from cancer increased from 9.8 million in 2001 to 14.5 million in 2014, owing to increasing adoption of better medical facilities. Moreover, increasing R&D activities by local players such as Spark Therapeutics, Inc. and Kite Pharmaceuticals and increasing product approvals by the U.S. FDA are boosting the market growth in North America.

Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to increasing focus of international player on strategies such as mergers and acquisitions. For instance, in February 2018, Merck acquired Viralytics Limited, a Sydney-based immune-oncology drug developer, to strengthen its immune-oncology drug pipeline. Moreover, increasing prevalence of various types of cancer in economies such as India and China is also expected to propel growth of the market.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oncology Drugs Market Estimated to Record Highest CAGR by 2026 With Top Companies Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer here

News-ID: 1802892 • Views: 130

More Releases from Coherent Market Insights - Pharmaceutical Industry

Pediatric Nutrition Market is Booming 2019 by Top Key Players Reckitt Benckiser …
Pediatric nutrition is an important source of nutritional supplement for babies during their formative years. These products are available in milk-based, Soy-based, amino acid-based, and organic forms. These nutritional products support brain development and also helps in the management of allergies and metabolic disorder. Highest number of births are recorded in Asia Pacific, and hence, the region holds maximum opportunity for market players. Lactose intolerance, allergy to cow’s protein milk,
Dravet Syndrome Treatment Market: Business Planning Research, Reviews & Comparis …
Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously
Cystic Fibrosis Market Headed for Growth and Global Expansion by 2026 With Top P …
Cystic fibrosis (CF) is a genetic disorder that usually affects the lungs and may also affect the pancreas, kidneys, liver, and intestine. Long-term repercussions including difficulty in breathing and coughing as a result of recurrent lung infections can be seen in CF. Some of the other signs and symptoms include sinus infections, poor growth, infertility in males, fatty stool, and guild of the fingers and toes. Different individuals may have
Glycosylated Peptide Market to Perceive Substantial Growth During 2018–2026 Wi …
Peptide drugs are potential therapeutic agent used against several disease attributing to its features high activity, target specificity, low toxicity, and minimal non-specific or drug–drug interactions. The low physicochemical properties such as poor membrane permeability and low target specific action when administered orally demands for improved peptide drug. Glycosylation of peptides is a promising strategy to modulate the physicochemical properties of peptide drugs and for penetration of peptides across biological

All 880 Releases